Block-Online Multi-Channel Speech Enhancement Using DNN-Supported Relative Transfer Function Estimates

This work addresses the problem of block-online processing for multi-channel speech enhancement. Such processing is vital in scenarios with moving speakers and/or when very short utterances are processed, e.g., in voice assistant scenarios. We consider several variants of a system that performs beamforming supported by DNN-based voice activity detection (VAD) followed by post-filtering. The speaker is targeted through estimating relative transfer functions between microphones. Each block of the input signals is processed independently in order to make the method applicable in highly dynamic environments. Owing to the short length of the processed block, the statistics required by the beamformer are estimated less precisely. The influence of this inaccuracy is studied and compared to the processing regime when recordings are treated as one block (batch processing). The experimental evaluation of the proposed method is performed on large datasets of CHiME-4 and on another dataset featuring moving target speaker. The experiments are evaluated in terms of objective and perceptual criteria (such as signal-to-interference ratio (SIR) or perceptual evaluation of speech quality (PESQ), respectively). Moreover, word error rate (WER) achieved by a baseline automatic speech recognition system is evaluated, for which the enhancement method serves as a front-end solution. The results indicate that the proposed method is robust with respect to short length of the processed block. Significant improvements in terms of the criteria and WER are observed even for the block length of 250 ms.Comment: 10 pages, 8 figures, 4 tables. Modified version of the article accepted for publication in IET Signal Processing journal. Original results unchanged, additional experiments presented, refined discussion and conclusion

Determining the Short-Range Spin Correlations in Cuprate Chain Materials with Resonant Inelastic X-ray Scattering

We report a high-resolution resonant inelastic soft x-ray scattering study of the quantum magnetic spin-chain materials Li2CuO2 and CuGeO3. By tuning the incoming photon energy to the oxygen K-edge, a strong excitation around 3.5 eV energy loss is clearly resolved for both materials. Comparing the experimental data to many-body calculations, we identify this excitation as a Zhang-Rice singlet exciton on neighboring CuO4-plaquettes. We demonstrate that the strong temperature dependence of the inelastic scattering related to this high-energy exciton enables to probe short-range spin correlations on the 1 meV scale with outstanding sensitivity.Comment: 5 pages, 4 figure

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years